Article Information
PubMed
Print ISSN
Online ISSN
History
- Received March 19, 2004
- Accepted June 9, 2004
- Published online August 20, 2004.
Article Versions
- Earlier version (June 10, 2004 - 09:49).
- You are viewing the most recent version of this article.
Copyright & Usage
The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Stuart Emanuel,
- Robert H. Gruninger,
- Angel Fuentes-Pesquera,
- Peter J. Connolly,
- Jennifer A. Seamon,
- Susan Hazel,
- Rose Tominovich,
- Beth Hollister,
- Cheryl Napier,
- Michael R. D'Andrea,
- Michael Reuman,
- Gilles Bignan,
- Robert Tuman,
- Dana Johnson,
- David Moffatt,
- Mark Batchelor,
- Anne Foley,
- James O'Connell,
- Rodger Allen,
- Martin Perry,
- Linda Jolliffe and
- Steven A. Middleton
- Cancer Therapeutics Research (S.E., R.H.G., A. F.-P., P.J.C., J.A.S., M.R., G.B., L.J., S.A.M.) and Oncology Research (R.To., M.R.D., R.Tu., D.J.], Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey; Institute of Medical and Veterinary Science, Adelaide, Australia (S.H.); Piedmont Research Center, Morrisville, North Carolina (B.H., C.N.); and Celltech Research, Limited, Slough, United Kingdom (D.M., M.B., A.F., J.O., R.A., M.P.)
- Address correspondence to:
Dr. Stuart Emanuel, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Raritan, NJ 08869. E-mail: semanuel{at}prdus.jnj.com
Statistics from Altmetric.com
Article usage
In this issue
A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models
